| 1 |
33390067 | In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy. | 2021 May |
1 |
| 2 |
34659899 | Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations. | 2021 |
3 |
| 3 |
32910995 | Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells. | 2020 Oct |
1 |
| 4 |
26864341 | Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. | 2016 Apr 28 |
1 |
| 5 |
27014420 | BCR: a new target in resistance mediated by BCR/ABL-315I? | 2016 Jan |
1 |
| 6 |
24586514 | Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia. | 2014 |
7 |
| 7 |
23319824 | Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia. | 2013 Mar 15 |
1 |